US real pricing gains are the single largest driver of global revenue growth for a typical biopharma multinational. Growing rebates and point-of-sale assistance levels are driving an expanding list-to-net gap. Manufacturers’ pricing concessions vary greatly by product category; as such the relative rates of change in companies’ net pricing are largely determined by the categories in which they compete, and their products’ differentiation levels within these categories.

Given the growing divergence between list and net, and the variance in list-to-net percentages across products, market segments, and manufacturers, it is essential to track net pricing.

Our US brand pricing dataset consists of list and estimated net pricing for approximately 1,000 brand drugs with disclosed US product-level sales from approximately 100 currently or previously publicly-traded firms. The products and companies we capture account for substantially more than 90 percent of US branded prescription net sales. For each product, we capture list pricing and unit volume, and calculate estimated net pricing, by quarter, as far back as 1Q07. Products are aggregated by therapeutic category (e.g. HCV, COPD, etc.) and by company to allow analysis of pricing at any meaningful level of aggregation (i.e. product, company, market segment, and/or whole industry). The tool allows users to determine the contribution of US net pricing to companies’ overall revenue growth, and to identify companies with more or less stable US net pricing outlooks.